Fuan Pharmaceutical Group Ningbo Team Pharmaceutical Co., Ltd.
-
Founded in:
1992-08-12 -
Country:
China -
Address:
No. 366, Anping Road, Zhaobaoshan Street, Zhenhai District, Ningbo City, Zhejiang Province -
Tax NO.:
91330211144072003N -
Registered Funds:
415 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Furosemide |
1. Effect on water and electrolyte excretion: It can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, etc.; by inhibiting the active reabsorption of NaCl by the thick wall segment of the renal tubular loop, it reduces the osmotic pressure gradient difference of the medullary interstitial fluid, resulting in increased excretion of water, Na, and Cl-. 2. Effect on hemodynamics: It inhibits the activity of prostaglandin degrading enzymes, increases the content of prostaglandin E2, dilates blood vessels, reduces renal vascular resistance, and increases renal blood flow; it dilates pulmonary capacitance veins, reduces the permeability of pulmonary capillaries, reduces the amount of blood returning to the heart, and reduces the left ventricular end-diastolic pressure, which is helpful for the treatment of acute left heart failure.
More
1. Effect on water and electrolyte excretion: It can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, etc.; by inhibiting the active reabsorption of NaCl by the thick wall segment of the renal tubular loop, it reduces the osmotic pressure gradient difference of the medullary interstitial fluid, resulting in increased excretion of water, Na, and Cl-. 2. Effect on hemodynamics: It inhibits the activity of prostaglandin degrading enzymes, increases the content of prostaglandin E2, dilates blood vessels, reduces renal vascular resistance, and increases renal blood flow; it dilates pulmonary capacitance veins, reduces the permeability of pulmonary capillaries, reduces the amount of blood returning to the heart, and reduces the left ventricular end-diastolic pressure, which is helpful for the treatment of acute left heart failure. |
54-31-9 | 49 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| LEVOFLOXACIN LACTATE |
This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, and gonococci; it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.
More
This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, and gonococci; it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc. |
294662-18-3 | 11 |